Cabozantinib (Cometriq)
Jump to navigation
Jump to search
General information
Class/mechanism: Small molecule that inhibits multiple tyrosine kinases: MET, VEGFR2, RET, and KIT.[1][2]
Route: Oral
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert.
Patient drug information
Not available